ESR1 and breast cancer: Rexer and colleagues proposed a clinical trial based on a neoadjuvant treatment to determine the tolerability and effects of a 2-week protocol with a very low carbohydrate KD in combination with letrozole for patients with early-stage operable ER+ BC.